- Home
- CNTB vs ANL Comparison
CNTB vs ANL Comparison
Compare CNTB & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- ANL
- Stock Information
- Founded
- CNTB 2012
- ANL 2004
- Country
- CNTB United States
- ANL Cayman Islands
- Employees
- CNTB N/A
- ANL 123
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- CNTB Health Care
- ANL
- Exchange
- CNTB Nasdaq
- ANL Nasdaq
- Market Cap
- CNTB 44.2M
- ANL 54.2M
- IPO Year
- CNTB 2021
- ANL 2023
- Fundamental
- Price
- CNTB N/A
- ANL N/A
- Analyst Decision
- CNTB Strong Buy
- ANL Hold
- Analyst Count
- CNTB 2
- ANL 1
- Target Price
- CNTB $7.50
- ANL N/A
- AVG Volume (30 Days)
- CNTB 103.1K
- ANL 8.0K
- Earning Date
- CNTB 05-15-2025
- ANL 08-08-2025
- Dividend Yield
- CNTB N/A
- ANL N/A
- EPS Growth
- CNTB N/A
- ANL N/A
- EPS
- CNTB N/A
- ANL N/A
- Revenue
- CNTB $26,033,000.00
- ANL N/A
- Revenue This Year
- CNTB N/A
- ANL N/A
- Revenue Next Year
- CNTB N/A
- ANL N/A
- P/E Ratio
- CNTB N/A
- ANL N/A
- Revenue Growth
- CNTB N/A
- ANL N/A
- 52 Week Low
- CNTB $0.51
- ANL $1.10
- 52 Week High
- CNTB $1.60
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- CNTB 72.64
- ANL 43.16
- Support Level
- CNTB $1.02
- ANL $1.48
- Resistance Level
- CNTB $1.07
- ANL $1.57
- Average True Range (ATR)
- CNTB 0.09
- ANL 0.08
- MACD
- CNTB 0.01
- ANL 0.01
- Stochastic Oscillator
- CNTB 91.19
- ANL 29.41
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.